Medical records for a GVHD consultation in China: connect the transplant history, organ changes, and treatment response

Many patients have a large collection of GVHD records: transplant discharge summaries, monthly laboratory tests, biopsy reports, prescriptions from several specialties, and skin photographs stored on a phone. The challenge is showing how those pieces relate. When did symptoms start? Which medicines were being taken? What improved? Why was treatment changed? Without that sequence, a large folder may still leave the new clinician uncertain about the current problem.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

State the current diagnosis, original disease, transplant date, principal symptoms, and systemic treatment. Then list one to three questions for the receiving clinician. These might concern diarrhea returning during steroid reduction or the next step for skin sclerosis and restricted movement. Chronic GVHD diagnosis and grading require the actual organ findings; “severe GVHD” alone is not an adequate clinical summary.[1]
For respiratory symptoms or lung involvement, collect serial pulmonary-function reports with dates, relevant original chest imaging, and radiology reports. Note infection and treatment changes around each examination. Adult pulmonary GVHD-related BOS recommendations integrate physiology, imaging, and investigation of other causes.[7]
File names can combine the date with the organ or test name, with originals and translations kept together. Preserve units, reference ranges, formulation details, and uncertainty in the source wording. List unavailable records and whether the original hospital can supply them. Explicitly identifying a gap is more useful than leaving the receiving clinician to infer why a result is absent.

Quick answer

Full guide

A brief clinical index followed by dated original reports is a practical starting point. The index helps locate information; the originals preserve the evidence. The guidance below draws on GVHD assessment and supportive-care sources checked in September 2026. It identifies existing information that can be useful, rather than instructing patients to arrange extra tests simply to complete a checklist.

Put the consultation question on the first page

State the current diagnosis, original disease, transplant date, principal symptoms, and systemic treatment. Then list one to three questions for the receiving clinician. These might concern diarrhea returning during steroid reduction or the next step for skin sclerosis and restricted movement. Chronic GVHD diagnosis and grading require the actual organ findings; “severe GVHD” alone is not an adequate clinical summary.[1]

Include the date of the most recent admission, fever episode, or major treatment change and whether oxygen, intravenous nutrition, or another form of support is needed. The first page should point to important changes rather than reproduce every normal historical result. Organizing records must not delay care when the patient is deteriorating.

Preserve the transplant context

Bring the transplant-center summary with donor type, stem cell source, matching information, conditioning, and GVHD prophylaxis. Keep the original disease status around transplantation and details of important early infections or complications. Acute GVHD assessment depends partly on this clinical background, which helps explain the risks and possible causes at the time symptoms appeared.[2]

Patients do not need to translate every transplant parameter into their own medical conclusion. Retain unfamiliar abbreviations and ask the original center to clarify them. If more than one transplant occurred, separate the dates and details so that results from the first episode are not inadvertently placed in the second. Missing medicine names should be obtained from records rather than reconstructed from family memory.

Build an event-based GVHD timeline

Arrange the first symptoms, diagnostic assessments, major organ changes, treatment additions, reductions, and hospitalizations chronologically. Acute, chronic, and overlap patterns are not defined solely by the number of days since transplantation. Terminology also distinguishes refractory disease, dependence, and intolerance.[3] Recording what happened is more reliable than trying to relabel the disease independently.

For example, “bowel frequency increased after steroid reduction, followed by stool testing and a treatment change” preserves the facts. “The disease became resistant again” already assumes an interpretation that may need review. Link each event to its clinic or discharge record. If two centers reached different assessments, keep both with their dates instead of submitting only the opinion the family prefers.

Record why each systemic treatment ended

For every systemic medicine, list its generic name, start and stop dates, major dose changes, the organ problem being treated, and the reason it ended. Lack of effect, unacceptable toxicity, interrupted supply, and planned reduction after improvement have different implications. Subsequent decisions in current acute GVHD guidance require an accurate account of previous treatment exposure and response.[4]

Record concurrent treatment too. If a new medicine and an increased corticosteroid dose began together, improvement cannot automatically be attributed entirely to the new agent. The clinician will assess the combined course. For a child or anyone receiving weight-based treatment, relevant weight measurements can help explain why a prescribed amount changed over time.

Make organ changes comparable across visits

NIH chronic GVHD response assessment uses organ-specific measures. Skin, mouth, eyes, lungs, and joints are not evaluated with one interchangeable score.[5] Collect previous organ assessments, symptom questionnaires, range-of-motion records, and photographs that show change. Label photographs by date and site and retain the original image without filters that alter skin appearance.

Repeated views of the same area are usually easier to interpret than numerous close-ups with no location or date. Brief functional observations can add context: ability to open the mouth for meals, fasten buttons, or walk the usual distance. Patient observations complement clinical measurements, not replace them. New areas of disease should not be omitted merely to keep a photographic series visually consistent.

Keep the specimen site and uncertainty in pathology reports

For skin, gastrointestinal, or other biopsies, provide the complete report and indicate whether corticosteroids or other immune treatments had already begun when the sample was taken. NIH pathology recommendations emphasize interpretation within the clinical setting; sampling, preceding treatment, and alternative causes can affect findings.[6]

Wording such as “compatible with,” “suggestive of,” or “cannot exclude” should survive translation. These phrases should not all become “confirmed GVHD.” Ask the receiving hospital whether slide review, blocks, or additional testing are actually required and what transfer arrangements apply. Do not independently mail tissue materials or repeat an invasive biopsy simply because an international consultation is planned.

Submit complete lung-function reports rather than a single percentage

For respiratory symptoms or lung involvement, collect serial pulmonary-function reports with dates, relevant original chest imaging, and radiology reports. Note infection and treatment changes around each examination. Adult pulmonary GVHD-related BOS recommendations integrate physiology, imaging, and investigation of other causes.[7]

“Lung function 60%” does not identify the measurement, reference value, or trend. Preserve named variables such as FEV1, the units, predicted values, and any quality comments. If oxygen is used, document the actual prescription and circumstances of use. The receiving team can then judge the need for further testing and travel review; patients should not alter support on the basis of a summarized number.

Include specialty records in the same clinical package

Eye records should preserve the diagnosis, ocular-surface and corneal findings, eye pressure where recorded, and local treatment. Oral records should describe pain, lesions, infection assessment, and effects on eating. EBMT material explains why both local GVHD and treatment-related complications require specialist interpretation.[8] These problems can be missed if only hematology correspondence is provided.

Where relevant, include dermatology, swallowing, genital, and rehabilitation assessments. NIH supportive-care guidance covers these potentially persistent concerns.[9] Mark local medicines still in use and reviews not yet completed. The index should make it clear which aspects of care need continuation rather than allowing a new systemic prescription to obscure existing organ-specific plans.

Keep pathogen details and susceptibility results

Provide recent and important previous cultures, pathogen tests, viral monitoring, and treatment records. Resistant organisms and serious drug allergies belong in a prominent place. Distinguish anti-infective medicines used for active infection from those prescribed for prevention. Long-term transplant recommendations emphasize prevention and immune recovery, so these medicines should not disappear when a new institution rewrites the prescription.[10]

A cropped screenshot may omit the specimen type, collection date, or full interpretation. Obtain the complete result where possible. A negative test is also tied to its sampling conditions and date; a result from months earlier should not be summarized as proof of no infection now. New symptoms may require fresh clinical assessment even when previous investigations were negative.

Make the current prescription identifiable across countries

List generic and brand names, formulation, strength, actual amount taken, and timing. Include systemic GVHD treatment, prevention, acid suppression, eye drops, topical medicines, and supplements. The Chinese belumosudil information describes interactions with some accompanying medicines, so an apparently routine additional prescription may matter.[11]

Clear packaging photographs can support the list, but should not replace it. The 2026 US ruxolitinib information includes different formulations, illustrating why the actual preparation needs to be preserved in an international record. A new overseas formulation does not establish Chinese availability of the same product.[12] Record missed doses, inability to take medicine after vomiting, or self-made changes honestly so that clinicians can understand actual exposure rather than only the intended prescription.

Separate chimerism and original-disease follow-up from GVHD activity

Donor chimerism describes cellular origin and has a different purpose from assessment of GVHD activity. EBMT chimerism guidance explains the clinical uses of these measurements.[13] Existing marrow, measurable residual disease, or other original-disease follow-up reports can be included, but complete donor chimerism should not be used to claim that GVHD is absent or that malignancy cannot recur.

Transfusion history, blood-group considerations, renal and liver function, and other major complications may also influence current care. Submit existing information and let clinicians decide what needs updating. The record list is intended to prevent omissions, not to create an independent reason for another marrow procedure or a full new cancer work-up before the appointment.

Check the format, dates, and translation before submission

File names can combine the date with the organ or test name, with originals and translations kept together. Preserve units, reference ranges, formulation details, and uncertainty in the source wording. List unavailable records and whether the original hospital can supply them. Explicitly identifying a gap is more useful than leaving the receiving clinician to infer why a result is absent.

Use the destination hospital's official channel to confirm accepted formats, the submission route, and whether paper copies are required. Peking University People's Hospital describes its international appointment process and current limits on international telemedicine; sending files is not equivalent to completing a remote diagnosis.[14]

At the consultation, confirm how the new assessment and prescription will be supplied for the original transplant center and home clinician. A practical record package allows another team to follow the clinical story, distinguish unresolved questions from established findings, and continue necessary care. Its value lies in making the evidence understandable rather than maximizing the number of attachments.

References

NIH. Chronic GVHD diagnosis and staging: https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/
EBMT Handbook. Acute GVHD: https://www.ncbi.nlm.nih.gov/books/NBK608233/
EBMT/NIH/CIBMTR. Standardized GVHD terminology: https://pmc.ncbi.nlm.nih.gov/articles/PMC6786777/
ASTCT. Acute GVHD treatment recommendations, 2026: https://pubmed.ncbi.nlm.nih.gov/42155643/
NIH. Chronic GVHD response assessment: https://pmc.ncbi.nlm.nih.gov/articles/PMC4744804/
NIH. Chronic GVHD pathology working-group recommendations: https://pmc.ncbi.nlm.nih.gov/articles/PMC4359636/
ERS/EBMT. Adult pulmonary chronic GVHD-related BOS recommendations: https://publications.ersnet.org/lookup/pmid/38485149
EBMT Handbook. Ocular and oral complications: https://www.ncbi.nlm.nih.gov/books/NBK608294/
NIH. Ancillary therapy and supportive care: https://pmc.ncbi.nlm.nih.gov/articles/PMC4821166/
International long-term transplant screening and prevention recommendations, 2023 update: https://pmc.ncbi.nlm.nih.gov/articles/PMC11181337/
Sanofi China. Belumosudil prescribing information: https://www.sanofi.cn/assets/dot-cn/pages/docs/products/prescription-products/rezurock-cn-20260122.pdf
FDA. Ruxolitinib prescribing information, 2026: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217180s001lbl.pdf
EBMT Handbook. Chimerism analysis: https://www.ncbi.nlm.nih.gov/books/NBK608246/
Peking University People's Hospital. International patient FAQ: https://english.pkuph.cn/care/overview_g7yU_57.html